Fredun Pharmaceuticals Ltd.

As of June 30, 2026, Fredun Pharmaceuticals Ltd. carries a market capitalization of 15.55B, placing it among publicly traded companies globally. Its enterprise value stands at 15.55B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Fredun Pharmaceuticals Ltd. has 16.54M shares outstanding.

As of June 30, 2026, Fredun Pharmaceuticals Ltd. trades at a trailing price-to-earnings ratio of 32.88.

As of June 30, 2026, Fredun Pharmaceuticals Ltd. trades at an EV/EBITDA multiple of 14.10 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.10 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 15.57 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 15.55B versus a market cap of 15.55B, with the gap driven by net debt and cash on the balance sheet.

These figures are as of June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The company generates approximately 14.88M in revenue per employee across its workforce of 498.50, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Fredun Pharmaceuticals Ltd. recorded 146.86M in income tax expense. That works out to an effective tax rate of 25.10, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 585.08M, leaving 438.22M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Fredun Pharmaceuticals Ltd.'s stock has gained approximately 151.30% over the past 52 weeks. The 50-day moving average sits at 1,425.82, while the 200-day moving average is 888.60.

Over the twelve months ended June 30, 2026, Fredun Pharmaceuticals Ltd. generated 7.42B in revenue and converted that into 438.22M in net income, yielding earnings per share of 27.46. EBITDA reached 1.10B, while operating income came in at 998.92M.

Over the twelve months ended June 30, 2026, Fredun Pharmaceuticals Ltd. posted a gross margin of 25.36, reflecting its pricing power and cost economics. The operating margin of 13.47 and net profit margin of 5.91 provide insight into operational efficiency.

Fredun Pharmaceuticals Ltd.'s most recent stock split took place on July 16, 2026 with a 1:3 split ratio.